Chengdu Brilliant Pharmaceutical Co., Ltd. (referred to as "Brilliant Pharmaceuticals") is an innovation-driven international pharmaceutical company. It is a high-tech enterprise headquartered in Chengdu, China, dedicated to the innovative R&D, production, and sales of high-quality medicines. The company mainly focuses on innovative drug development, high value medicines and APIs. Our business has comprehensively covered the entire pharmaceutical industry chain, including intermediates (INT), APIs, and Finished Drug Formulations (FDFs), which encompass Chemical Drugs (including Radiopharmaceuticals), Biological Drugs, and Chinese Patent Medicine.

Brilliant Pharmaceuticals adheres to an innovation-driven strategy to address unmet clinical needs and continue to advance access to medicines. Focusing on tumors, cardiovascular diseases, neurological diseases, autoimmune diseases, and rare diseases, the company has established a competitive innovative drug R&D pipeline, which are based on several cutting-edge technology platforms, such as RNAi therapeutics, radionuclide drug conjugates (RDC), antibody-drug conjugates (ADC), gene and cell therapy etc.

More than ten years of development, the company focuses on the pharmaceutical field and continues to cultivate, with profound APIs and formulations integrated industry strength. At its production bases across the country (including Hong Kong), Brilliant Pharmaceuticals has always adhered to excellent manufacturing, continuously enhancing the lean management of the entire process that centering on quality and efficiency, and comprehensively building a production quality management system comliant with international standards.

In the future, Brilliant Pharmaceuticals will uphold the mission of "Let everyone have health, make life more energetic", and will continue to enhance our innovation capabilities and promote internationalization to achieve long-term value growth and sustainable development.

（Last updated Jan, 2026）